Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Opko Health (OPK)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX – Research Report) and Opko Health (OPK – Research Report).
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
BioNTech SE (BNTX)
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE today and set a price target of $140.00. The company’s shares closed last Thursday at $120.54.
According to TipRanks.com, Papadakis is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioNTech SE with a $140.13 average price target, representing a 23.1% upside. In a report issued on April 14, Morgan Stanley also maintained a Buy rating on the stock with a $140.00 price target.
See the top stocks recommended by analysts >>
Opko Health (OPK)
Opko Health received a Hold rating from J.P. Morgan analyst Eric Joseph today. The company’s shares closed last Thursday at $1.46.
According to TipRanks.com, Joseph is a 3-star analyst with an average return of
Opko Health has an analyst consensus of Strong Buy, with a price target consensus of $2.56.
Read More on BNTX:
Disclaimer & DisclosureReport an Issue
- BioNTech to Showcase Oncology Advances at AACR 2025
- RFK Jr. may reverse CDC’s Covid-19 recommendation for children, Politico says
- Novavax’s COVID-19 vaccine shows lower side effects vs. Pfizer-BioNTech’s
- BioNTech price target raised to $140 from $139 at Morgan Stanley
- BioNTech SE Announces Virtual Annual General Meeting for 2025
